Beacon Biosignals is transforming precision medicine for the brain, from clinical development to clinical care. For Life Sciences partners, we offer the leading at-home EEG platform for clinical development of novel therapeutics for neurological, psychiatric, and sleep disorders. Our Diagnostics business is building the most comprehensive at-home platform for precision diagnostics, combining EEG and cardiopulmonary signals to deliver reimbursable assessments for sleep and central nervous system disorders. Together, we're changing the way patients are diagnosed and treated for any disorder that affects brain physiology.

The Regional Sales Manager will sit within the Beacon Dx commercial organization and will be responsible for driving adoption of Beacon HST across the Midwest. This role reports directly to the National Vice President of Clinical Sales and does not initially manage direct reports. The role owns a high-priority territory that includes Illinois, Colorado, Nebraska, Kansas, Minnesota, Iowa, and Missouri . Preferred candidate locations include Chicago, Denver, Kansas City or St. Louis, with preference for major metro access to support field travel and customer engagement.

Beacon Dx is building the next generation of home-based diagnostics by combining EEG and cardiopulmonary signals into a unified platform. This is not a transactional device role. Success requires the ability to sell into complex clinical environments, influence diagnostic pathways, and establish Beacon as a standard of care alternative to legacy HST solutions. The right candidate will convert clinical credibility into commercial scale by opening new accounts, expanding strategic accounts, displacing incumbent solutions, and partnering cross-functionally to ensure utilization after the sale.

What success looks like:

Own full Midwest territory performance, including pipeline creation, deal progression, revenue attainment, and forecast accuracy.
Drive new business and expand strategic accounts across sleep labs, IDTFs, health systems, and multi-site clinical organizations.
Lead with clinical differentiation by translating EEG-based diagnostics, workflow advantages, and data quality into clear value propositions for physicians, administrators, and technical stakeholders.
Maintain disciplined CRM hygiene in Zoho, including timely follow-up, clean opportunity staging, accurate close dates, and reliable revenue forecasting.
Develop relationships with sleep physicians, pulmonologists, neurologists, technical directors, administrators, and executive decision-makers across complex buying committees.
Execute high-impact product demonstrations and support clinical validation of Beacon HST in real-world customer environments.
Attend regional and national conferences to generate leads, strengthen relationships, identify KOLs, and support market education.
Partner with Clinical Enablement, Operations, Product, Customer Experience, and Logistics to support onboarding, utilization, retention, and reorder consistency.
Maintain confidentiality, integrity, and availability of Protected Health Information in accordance with HIPAA standards.
Demonstrate consistent quota attainment, competitive displacement, multi-site account growth, and regional KOL development.

What you will bring:

7 or more years of medical device or healthcare sales experience.
4 or more years in sleep diagnostics, cardiopulmonary diagnostics, neurology-adjacent diagnostics, or a closely related clinical market.
Proven record of meeting or exceeding sales targets in a field-based territory role.
Demonstrated ability to sell into complex healthcare environments with multiple stakeholders and longer buying cycles.
Strong clinical curiosity and the ability to explain diagnostic differentiation without overcomplicating the message.
Excellent communication, negotiation, executive presence, and presentation skills.
Ability to operate independently, prioritize the right accounts, manage competing demands, and build structure in an underdeveloped territory.
Proficiency with CRM systems, with Zoho experience preferred, and Microsoft Office Suite.
Willingness to travel extensively throughout the Midwest region.
Bachelor’s degree required. Advanced business, clinical, or healthcare-related education preferred.
High ownership, strong field discipline, coachability, intellectual honesty, and comfort operating in a competitive growth-stage environment.

The base salary range for this role is determined based on past experience, specific skills and qualifications. The base salary is one component of the total compensation package, which includes equity, PTO and other benefits.

At Beacon, we've found that cultural and scientific impact is driven most by those that lead by example. As such, we're always seeking new contributors whose work demonstrates an avid curiosity, a bias towards simplicity, an eye for composability, a self-service mindset, and - most of all - a deep empathy towards colleagues, stakeholders, users, and patients. We believe a diverse team builds more robust systems and achieves higher impact.

About the company

Beacon Biosignals develops an EEG-based neurobiomarker platform for precision medicine in neurology and psychiatry. Its core offering provides quantitative assessments of how treatments affect EEG and sleep data to speed up clinical trials and inform dose selection. By analyzing EEG signals alongside PK/PD relationships, the platform helps identify dosing that achieves the best balance of efficacy and safety, supporting the development of new therapies. The company differentiates itself through its proprietary EEG biomarkers and a focus on integrating brain activity data into trial design, enabling closer monitoring of treatment impact for biopharma, academic medical centers, and neurotechnology developers. Beacon Biosignals aims to advance personalized treatment for neurological and psychiatric diseases and improve the efficiency of clinical development in precision medicine.

Company Size

51-200

Company Stage

Series B

Total Funding

$127.5M

Headquarters

Boston, Massachusetts

Founded

2019

Get referred to Beacon Biosignals

See people who can refer or advise you

Simplify's Take

What believers are saying

April 6, 2026 Series B extension added $11 million and Samsung Next.
November 19, 2025 Takeda expansion promises up to $109 million in milestones.
December 16, 2025 Harmony deal and SLEEP 2026 data expand hypersomnia traction.

What critics are saying

Takeda and Harmony dominate validation; partner pullback would crush 2027 revenue visibility.
Beacon depends on pharma accepting EEG endpoints; failed trials kill biomarker commercialization.
FDA or algorithm-performance setbacks could block Waveband-driven trials and erase Beacon’s core moat.

What makes Beacon Biosignals unique

Beacon’s FDA-cleared Waveband enables PSG-quality at-home EEG, not consumer proxy signals.
Beacon’s 2025-2026 platform spans neurology, psychiatry, and sleep medicine with one dataset.
Beacon’s biomarker stack targets clinical endpoints and PK/PD, not only monitoring.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity
Paid Vacation
Hybrid Work Options

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

-2%

Associated Press

Oct 22nd, 2026

Beacon Biosignals acquires Snap Diagnostics to bring EEG home sleep testing to all 50 states

Beacon Biosignals, a Boston-based neurotechnology company, has acquired Snap Diagnostics, a home sleep testing provider serving patients in all 50 US states. The deal more than doubles Beacon's patient reach and makes it one of the largest home sleep testing providers in the country. Beacon plans to offer home sleep tests that measure brain activity (EEG) from 2027, using its FDA 510(k)-cleared Waveband headband and AI analysis. Unlike wearables that estimate sleep indirectly, the headband captures sleep fragmentation linked to obstructive sleep apnea. Snap handles shipping, scoring, interpretation, and billing, so primary care and other non-sleep clinicians can order tests without in-house expertise. It will stay a subsidiary, with no change to its name or services. "Sleep happens in the brain," said chief executive officer Jacob Donoghue.

True North Radio Network

Oct 22nd, 2026

Beacon Biosignals acquires Snap Diagnostics, paving the way for eeg-enabled home sleep testing in every care setting.

Beacon Biosignals acquires Snap Diagnostics, paving the way for eeg-enabled home sleep testing in every care setting. * Oct 22, 2026 BOSTON, Oct. 22, 2026 (GLOBE NEWSWIRE) - Beacon Biosignals, a leading AI-powered precision neurotechnology company, today announced that it has acquired Snap Diagnostics, a premier home sleep testing (HST) provider serving patients in all 50 states. The acquisition more than doubles Beacon's patient reach, making it one of the largest HST providers in the United States and establishing a national channel to bring EEG-enabled home sleep testing to more patients starting in 2027. Consumer wearables and cardiopulmonary devices estimate sleep indirectly from signals like movement, heart rate, and airflow. Beacon's FDA 510(k)-cleared Waveband headband measures the brain's electrical activity (EEG) directly, capturing the sleep fragmentation behind many of the daytime symptoms and long-term risks of obstructive sleep apnea (OSA). Combined with AI-driven analysis from the Beacon Platform, EEG-enabled home testing gives clinicians a more complete picture of OSA and disturbed nighttime sleep without an overnight lab visit. "Sleep happens in the brain, so measuring brain activity is essential to fully understanding sleep and its impact on health," said Jacob Donoghue, MD, PhD, CEO and co-founder of Beacon Biosignals. "Snap gives us the national reach to bring EEG-enabled testing to nearly every clinician who sees patients at risk for sleep disorders. We believe sleep diagnostics will soon extend well beyond sleep apnea, with the potential for at-home neurophysiology to help identify early signs of neurodegenerative disease and support more personalized psychiatric care. This acquisition is a major step toward that future." Snap's end-to-end service lets primary care physicians, advanced practice providers, telehealth providers, and specialists such as psychiatrists, cardiologists, endocrinologists, and weight management physicians order a home sleep test without in-house sleep expertise. Snap ships the test directly to the patient, with results scored and interpreted by qualified sleep professionals in accordance with American Academy of Sleep Medicine (AASM) guidance. As an Independent Diagnostic Testing Facility (IDTF), Snap also bills Medicare and commercial insurers directly, allowing clinicians to offer home sleep testing without managing equipment, logistics, or billing. "Nearly one in three Americans experience sleep symptoms, yet there are only about 6,000 board-certified sleep physicians in the country," said Donoghue. "By making sleep testing more accessible through primary care and other specialties, we can help identify more patients who need evaluation and connect them with the right care. We see sleep specialists as essential partners in this effort, helping more patients benefit from their expertise and ensuring those with complex needs receive the specialized care they deserve." Beacon's acquisition of Snap expands its reach in OSA diagnostics while creating a pathway to bring its neurophysiology and AI capabilities into broader clinical care. Beacon's technology supports clinical trials across neurological, psychiatric, and sleep disorders with more than half of the world's top 10 biopharmaceutical companies, including Johnson & Johnson, Bristol Myers Squibb, UCB, Harmony, and Takeda. These partners rely on clinically validated EEG and AI-derived biomarkers from the Beacon Platform, powered by a foundation model of brain activity trained on millions of hours of EEG, to evaluate the next generation of brain health therapies. By bringing this platform into clinical care, Beacon aims to bridge drug development and patient care, applying the same underlying technology used to develop new treatments to help clinicians better diagnose and manage the patients those treatments are designed to help. Frequently Asked Questions Q: What is EEG-enabled home sleep testing, and when will it be available? A: EEG-enabled home sleep testing adds direct measurement of brain activity to the cardiopulmonary signals a standard home sleep test captures, such as airflow, respiratory effort, and oxygen saturation. Beacon plans to bring EEG-enabled home sleep testing to more patients starting in 2027. Q: What does Beacon's acquisition of Snap Diagnostics mean for patients? A: More patients can access clinical-grade home sleep testing. Snap's end-to-end service is available in all 50 states, expanding Beacon's reach to healthcare providers outside the sleep specialty, where patients with undiagnosed sleep disorders often first seek care. Q: Will anything change for current Snap customers? A: No. For the foreseeable future, Snap will remain a subsidiary of Beacon Biosignals, with no change to its name or services. Q: Who can order a home sleep test through Snap Diagnostics? A: In addition to sleep specialists, sleep centers, and academic medical centers, Beacon can now serve healthcare providers outside the sleep specialty, including primary care physicians, advanced practice providers, telehealth providers, and other medical specialists. Q: Who interprets the sleep study results? A: Snap's sleep technicians score every Snap study, and trained specialists interpret it, consistent with AASM guidance that home sleep apnea test data be interpreted by, or under the oversight of, a board-certified sleep medicine physician. Ordering clinicians receive a completed interpretation without needing in-house sleep expertise. Q: Which patients are appropriate for home sleep testing? A: Under AASM guidance, home sleep apnea testing is appropriate for uncomplicated adult patients whose signs and symptoms indicate an increased risk of moderate-to-severe OSA, such as excessive daytime sleepiness combined with loud snoring or witnessed breathing pauses. Q: How is a Snap Diagnostics home sleep test billed? A: Snap is a Medicare-registered IDTF accredited by The Joint Commission, and it bills Medicare and commercial insurers directly. Clinicians place the order, and Snap takes care of the rest, from shipping the test to the patient through scoring, interpretation, and billing. About Beacon Biosignals Beacon Biosignals is transforming precision medicine for the brain. Its FDA-cleared, at-home EEG and cardiopulmonary devices deliver clinical-grade sleep diagnostics in patients' natural environments. The Beacon Platform applies AI/ML to stratify patients and generate digital endpoints for interventional clinical trials. It also helps characterize and track the progression of neurodegenerative, neuropsychiatric, and primary sleep disorders. Learn more at www.beacon.bio. About Snap Diagnostics Snap Diagnostics is a Medicare-registered Independent Diagnostic Testing Facility (IDTF) accredited by The Joint Commission. Snap provides a complete home sleep testing service, shipping tests directly to patients, with every study scored by Snap's sleep technicians and interpreted by its sleep specialists, available in all 50 states. Snap is a subsidiary of Beacon Biosignals. Learn more at snapdiagnostics.com. Media Contact Isabella Lazzareschi, Director of Marketing, Beacon Biosignals Media gallery

GlobeNewswire

Oct 19th, 2026

Beacon Biosignals partners with Project Sleep to shorten the path to diagnosis for people with idiopathic hypersomnia and narcolepsy.

Beacon Biosignals partners with Project Sleep to shorten the path to diagnosis for people with idiopathic hypersomnia and narcolepsy. The partnership connects Beacon's AI-driven neurotechnology with the patient-led advocacy community, expanding access to diagnosis and bringing patient voices directly into clinical research. BOSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) - Beacon Biosignals today announced a partnership with Project Sleep, the patient-led nonprofit organization working to raise awareness of sleep health, sleep equity, and sleep disorders. The partnership brings together Beacon's AI-driven neurotechnology platform and Project Sleep's national community of patients, advocates, and researchers to reach people living with idiopathic hypersomnia and narcolepsy earlier in their diagnostic journeys. People with idiopathic hypersomnia (IH) wait an average of 8 to 11 years for a diagnosis, and people with narcolepsy type 1 (NT1) wait 4 to 11 years (Zhang, 2025). During that time, patients are often misdiagnosed with major depressive disorder (MDD) or another psychiatric condition, or the picture is clouded by a diagnosis of obstructive sleep apnea (OSA). These diagnostic delays can have a severely detrimental impact on patients' education, employment, and quality of life. Beacon develops at-home diagnostics and clinical trial technology designed to target that gap directly. Through this partnership, the two organizations will identify undiagnosed patients, support people already diagnosed with better treatment pathways, and shorten the time between a first symptom and a clinical answer. "Improving patients' lives is central to Beacon's mission," says Jacob Donoghue, MD, PhD, and CEO of Beacon Biosignals. "Project Sleep has spent more than a decade building trust in this community and amplifying patient voices. Working alongside them enables us to use our technology to find and treat people with disorders of hypersomnia sooner." With Project Sleep, Beacon will run patient focus groups, giving the company structured input from patients and caregivers on the testing experience, and informing Beacon's national home sleep testing network. That network supports enrollment in clinical research, where Project Sleep plays a central role by connecting its community to sleep disorder studies from both industry and academic sponsors. "Our community has always been ready to participate in research and to help solve the diagnostic delay that so many of us lived through," adds Julie Flygare, JD, President and CEO of Project Sleep. "What has been missing is a way to relay those insights to the people building diagnostic tools and novel therapeutics. This partnership creates that link, and it treats patients as contributors rather than subjects." Founded in 2013 by Julie Flygare, who was diagnosed with narcolepsy at age 24, Project Sleep is one of the few sleep organizations led by someone living with the condition it serves. Its programs include the Sleep Helpline, a free national helpline for people facing sleep issues; Rising Voices, which has trained more than 190 patient advocates across 21 countries; and the Jack and Julie Narcolepsy Scholarship, the first national scholarship program for students with narcolepsy and idiopathic hypersomnia. Beacon and Project Sleep will begin joint work immediately, with Beacon participating in Project Sleep's 7th annual Sleep Advocacy Forum on October 26, 2026, in Washington, D.C. Learn more about Beacon Biosignals at www.beacon.bio. About Beacon Biosignals Beacon Biosignals is transforming precision medicine for the brain. Our FDA-cleared, at-home Waveband EEG and cardiopulmonary devices deliver gold-standard sleep diagnostics in patients' natural environments. The Beacon Platform applies AI/ML to stratify patients and generate clinically validated endpoints for interventional clinical trials, and tracks disease progression of neurodegenerative, neuropsychiatric, and primary sleep disorders in longitudinal and open label studies. We partner with leading pharmaceutical, biotechnology companies, and health systems across CNS disease in service of building the world's largest library of clinical and physiology data supporting scientific discovery and patient care. About Project Sleep Project Sleep is a 501(c)(3) nonprofit organization dedicated to raising awareness about sleep health, sleep equity, and sleep disorders. Founded in 2013, the organization educates and empowers individuals through events, campaigns, and programs that bring people together to talk about sleep as a pillar of health. Project Sleep holds a four-star rating from Charity Navigator and a Platinum Seal of Transparency from Candid, and is a member of the National Organization for Rare Disorders. Learn more at project-sleep.com. Media Contact Beacon Biosignals Isabella Lazzareschi, Director of Marketing [email protected]

Longevity.Technology

Jun 22nd, 2026

Beacon Biosignals showcases advanced AI sleep tech and clinical data at SLEEP 2026.

Beacon Biosignals showcases advanced AI sleep tech and clinical data at SLEEP 2026. Beacon Biosignals participated in SLEEP 2026, engaging clinicians, researchers and sleep medicine leaders. The company highlighted multiple presentations focused on automated sleep staging algorithms, machine learning-based arousal detection and a large-scale EEG foundation model designed for multi-device sleep analytics. Beacon also presented validation data for its Waveband device in hypersomnia disorders, developed in collaboration with Takeda and featured in an oral presentation, according to the company. For investors, the activity suggests ongoing progress toward building clinically relevant evidence around Beacon's digital biomarker and EEG analytics platform that could support future commercialization or partnership opportunities in sleep medicine and neurology. The emphasis on expert-level algorithm performance and large-scale EEG models indicates an effort to differentiate through technical depth and scalability, potentially positioning the business to serve biopharma trials and clinical endpoints. The company also promoted meeting availability at the conference as part of its business development outreach.

Simcast

Apr 20th, 2026

Beacon Biosignals targets neurology trial partners with fda-cleared Waveband EEG at AAN 2026.

Beacon Biosignals targets neurology trial partners with fda-cleared Waveband EEG at AAN 2026. Last updated: April 20, 2026 Beacon Biosignals is participating in the 2026 American Academy of Neurology Annual Meeting in Chicago. The company is showcasing its Waveband device, a novel technology for electroencephalogram (EEG) signal acquisition and analysis. This event marks a significant opportunity for the company to present its advancements in brain signal technology to a key audience of neurologists and researchers. * Beacon Biosignals' Waveband device is designed for advanced EEG signal acquisition and analysis. The device aims to provide more accurate and efficient data collection for neurological studies. The company's presence at the American Academy of Neurology Annual Meeting signifies its commitment to developing and promoting innovative solutions in the field of neurology. This participation allows for direct engagement with medical professionals and potential collaborators. The meeting is a premier event for showcasing the latest research and technologies in neurology.

Beacon Biosignals

Regional Sales Manager

About the job